A 58-year-old man with a history of small cell lung cancer presents to the emergency department with confusion and lethargy. His wife reports he has been increasingly drowsy over the past 3 days. On examination, he is oriented to person only, blood pressure is 128/82 mmHg, heart rate 88/min, and there is no clinical evidence of volume depletion or edema. Laboratory investigations reveal: Na⁺ 118 mEq/L, K⁺ 3.8 mEq/L, Cl⁻ 102 mEq/L, HCO₃⁻ 24 mEq/L, urine osmolality 580 mOsm/kg, serum osmolality 242 mOsm/kg, and urine Na⁺ 65 mEq/L. What is the most appropriate immediate management?

Explanation

## Clinical Diagnosis **Key Point:** This patient has Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secondary to small cell lung cancer, presenting with **severe symptomatic hyponatremia** (Na⁺ 118 mEq/L with confusion and lethargy) requiring immediate treatment with hypertonic saline. ### Diagnostic Reasoning The clinical picture is classic for SIADH: - **Euvolemic state:** No edema, normal blood pressure, no clinical signs of volume depletion - **Low serum osmolality (242 mOsm/kg)** with inappropriately high urine osmolality (580 mOsm/kg) — the kidney is concentrating urine despite dilute plasma - **Urine Na⁺ >40 mEq/L (65 mEq/L):** Excludes renal failure and hepatic cirrhosis; consistent with SIADH - **Known malignancy (SCLC):** A classic paraneoplastic cause of SIADH ### Why Hypertonic Saline Is the Correct Immediate Management Per Harrison's Principles of Internal Medicine and current guidelines (European Clinical Practice Guidelines 2014), **symptomatic hyponatremia — regardless of chronicity — requires immediate treatment with hypertonic (3%) saline** when neurological symptoms are present (confusion, lethargy, seizures, coma). | Symptom Severity | Na⁺ Level | Immediate Treatment | |-----------------|-----------|---------------------| | Severe (seizures, coma) | Any | 3% NaCl bolus 100 mL IV | | Moderate (confusion, lethargy) | <120 mEq/L | 3% NaCl at 0.5–2 mL/kg/hr | | Mild/asymptomatic | Any | Fluid restriction ± vaptans | **Clinical Pearl:** This patient has Na⁺ of **118 mEq/L** with **active neurological symptoms** (confusion, oriented to person only, lethargy). This constitutes **moderate-to-severe symptomatic hyponatremia** and is an indication for hypertonic saline regardless of the 3-day history. The goal is to raise Na⁺ by **4–6 mEq/L in the first few hours** to relieve cerebral edema, while not exceeding **8–10 mEq/L per 24 hours** to avoid osmotic demyelination syndrome (ODS). ### Correction Rate Targets (Harrison's / NBE Guidelines) 1. **Acute target:** Raise Na⁺ by 1–2 mEq/L/hr until symptoms resolve 2. **24-hour cap:** Do not exceed 10 mEq/L (some guidelines say 8 mEq/L in high-risk patients) 3. **48-hour cap:** Do not exceed 18 mEq/L total Fluid restriction alone is too slow to address active neurological compromise and is appropriate only for **asymptomatic or mildly symptomatic** chronic SIADH. ### Why Other Options Are Incorrect - **Normal saline + loop diuretics (B):** Used in **hypervolemic hyponatremia** (heart failure, cirrhosis). In SIADH, normal saline is hypotonic relative to the concentrated urine (urine osmolality 580 mOsm/kg), so it would paradoxically worsen hyponatremia. - **Desmopressin (C):** A vasopressin analogue — it increases ADH effect and is absolutely contraindicated in SIADH, where ADH activity is already inappropriately elevated. - **Fluid restriction to 500–800 mL/day (D):** Correct long-term management of asymptomatic SIADH, but **insufficient as immediate management** when the patient has active neurological symptoms (confusion, lethargy) and Na⁺ of 118 mEq/L. Fluid restriction acts over days and cannot rapidly correct the sodium deficit needed to relieve cerebral edema. **High-Yield:** The key distinction is **symptomatic vs. asymptomatic** hyponatremia — NOT acute vs. chronic. Neurological symptoms (confusion, lethargy) at Na⁺ 118 mEq/L mandate hypertonic saline as the immediate intervention, with careful rate monitoring to prevent ODS. *(Harrison's Principles of Internal Medicine, 21st ed., Chapter 49)*